

# Antipsychotic Treatment Selector

Charts revised December 2023. Full information available at [www.hiv-druginteractions.org](http://www.hiv-druginteractions.org)

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

	ATV/c	ATV/r	DRV/c	DRV/r	LPV/r	DOR	EFV	ETV	NVP	RPV oral	FTR	LEN	MVC	BIC/F/TAF	CAB oral	CAB/RPV	DTG	EVG/c/F/TAF	EVG/c/F/TDF	RAL	FTC/TAF	FTC/TDF	
<b>Atypical Antipsychotics</b>																							
Amisulpride	↔	↔	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Aripiprazole	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔	
Asenapine	↑♥	↓♥	↑	↓♥	↓♥	↔	↓♥	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔	
Clozapine	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔	
Olanzapine	↔	↓	↔	↓	↓	↔	↓♥	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Paliperidone	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔	
Quetiapine	↑a♥	↑a♥	↑a	↑a	↑a♥	↔	↓♥	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↑a	↑a	↔	↔	↔	
Risperidone	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
Zotepine	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔	
<b>Phenothiazines</b>																							
Chlorpromazine	↑♥	↑♥	↑	↑	↑♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Fluphenazine	↑♥	↑♥	↑	↑	↑♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Levomepromazine	↑♥	↑♥	↑	↑	↑♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Perazine	↑	↑	↑	↑	↑	↔	↓	↓	↓	↔	↔	↑	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Periciazine	↑	↑	↑	↑	↑	↔	↔♥	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑	↔	↔	↔	↔
Perphenazine	↑♥	↑♥	↑	↑	↑♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Pimozide	↑♥	↑♥	↑	↑	↑♥	↔	↓b	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Prochlorperazine	↑♥	↑♥	↑	↑	↑♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Thioridazine	↑♥	↑♥	↑	↑	↑♥	↓	↓♥	↓	↓	↓♥	↔♥	↑↓	↓	↓c	↔	↓	↔	↔	↑	↑	↔	↔	↔
<b>Others</b>																							
Haloperidol	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↑	↑	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
lloperidone	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Pipotiazine	↑♥	↑♥	↑	↑	↑♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Sulpiride	↔♥	↔♥	↔	↔	↔♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔	↔
Tiapride	↔♥	↔♥	↔	↔	↔♥	↔	↔♥	↔	↔	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↔	↔	↔	↔	↔
Ziprasidone	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↔	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔
Zuclophenthixol	↑♥	↑♥	↑	↑	↑♥	↔	↓♥	↓	↓	↔♥	↔♥	↑	↔	↔	↔	↔	↔♥	↔	↑	↑	↔	↔	↔

**Interactions with CAB/RPV long acting injections**

Pharmacokinetic interactions shown are mostly with RPV. QT interactions shown are with RPV.

**Interactions with Lenacapavir**

Residual LEN may affect exposure of sensitive CYP3A4 substrates initiated within 9 months after stopping subcutaneous LEN.

**Interactions with Ibalizumab**

None

**Interactions with Abacavir (ABC), Lamivudine (3TC), Tenofovir-DF (TDF) or Zidovudine (ZDV)**

ABC: No clinically relevant interactions expected.

3TC: No clinically relevant interactions expected.

TDF: No clinically relevant interactions expected.

ZDV: Potential additive haematological toxicity with chlorpromazine, clozapine, fluphenazine, periciazine, perphenazine, pipotiazine, quetiapine, thioridazine, zuclophenthixol.

**Colour Legend**

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dose adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

**Text Legend**

- ↑ Potential increased exposure of the antipsychotic
- ↓ Potential decreased exposure of the antipsychotic
- ↔ No significant effect
- ♥ One or both drugs may cause QT and/or PR prolongation. ECG monitoring is advised if coadministered with atazanavir or lopinavir. Efavirenz has a potential risk of QT prolongation relating specifically to homozygous carriers of CYP2B6\*6/\*6. Rilpivirine and fostemsavir were shown to prolong the QT interval at supratherapeutic doses. Caution is advised with rilpivirine. ECG monitoring is advised with fostemsavir and drugs with a known QT prolongation risk.
- ↑ Potential increased exposure of HIV drug
- ↓ Potential decreased exposure of HIV drug

**Notes**

- a Coadministration contraindicated in the European SPC, however, US Prescribing Information recommends quetiapine should be reduced to one sixth of the original dose if coadministered with a potent CYP3A4 inhibitor. The charts reflect the more cautious option.
- b The efavirenz European SPC (but no longer the US Prescribing Information) contraindicates coadministration citing competition for CYP3A4 by efavirenz as a potential mechanism for inhibition of pimoizide metabolism which may result in potential serious and/or life-threatening adverse events such as cardiac arrhythmias.
- c No effect on FTC or TAF is expected, but bictegravir concentrations may decrease.